Abstract
Multiple myeloma is the second most hematological malignancy, accounting for more than 10% of all blood cancers and 2% of annual cancer-related deaths due to lack of curable drugs. Novel and molecularly targeted anti-MM drugs are in urgent need. The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway plays a critical regulatory role in multiple myeloma pathophysiology, including survival, proliferation, migration, angiogenesis, as well as drug resistance, and has emerged as a key therapeutic target. Many potent inhibitors targeting this pathway have been developed and some have been moved for clinical evaluations for multiple myeloma. In this review, we highlighted the role of the PI3K/AKT pathway in the pathogenesis of multiple myeloma, and current advances in drug discovery for this class of inhibitors. Discovery strategies toward the PI3K/AKT inhibitors were also discussed.
Keywords: AKT, drug discovery, mTOR, multiple myeloma, phosphatidylinositol 3-kinase.
Current Medicinal Chemistry
Title:Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Volume: 21 Issue: 27
Author(s): J. Zhu, M. Wang, B. Cao, T. Hou and X. Mao
Affiliation:
Keywords: AKT, drug discovery, mTOR, multiple myeloma, phosphatidylinositol 3-kinase.
Abstract: Multiple myeloma is the second most hematological malignancy, accounting for more than 10% of all blood cancers and 2% of annual cancer-related deaths due to lack of curable drugs. Novel and molecularly targeted anti-MM drugs are in urgent need. The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway plays a critical regulatory role in multiple myeloma pathophysiology, including survival, proliferation, migration, angiogenesis, as well as drug resistance, and has emerged as a key therapeutic target. Many potent inhibitors targeting this pathway have been developed and some have been moved for clinical evaluations for multiple myeloma. In this review, we highlighted the role of the PI3K/AKT pathway in the pathogenesis of multiple myeloma, and current advances in drug discovery for this class of inhibitors. Discovery strategies toward the PI3K/AKT inhibitors were also discussed.
Export Options
About this article
Cite this article as:
Zhu J., Wang M., Cao B., Hou T. and Mao X., Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma, Current Medicinal Chemistry 2014; 21 (27) . https://dx.doi.org/10.2174/0929867321666140601204513
DOI https://dx.doi.org/10.2174/0929867321666140601204513 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melanoma
Current Cancer Therapy Reviews Anti-Interleukin-6 Receptor Antibody Therapy in Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Stent-Based Delivered Anti-Proliferative Drugs in the Prevention of Coronary Stent Restenosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Role of Adipocytokines in Atherogenesis and Atheroprogression
Current Drug Targets Kinase CK2 Inhibition: An Update
Current Medicinal Chemistry Multiple Myeloma Bone Marrow Niche
Current Pharmaceutical Biotechnology The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases
Current Protein & Peptide Science Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells
Current Cancer Drug Targets The Pim Kinases: New Targets for Drug Development
Current Drug Targets ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Sporadic Porphyria in a Patient with Stage II Melanoma Treated with Interferon α
Current Drug Safety Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials Pharmacokinetic Properties of Rituximab
Reviews on Recent Clinical Trials Hck Inhibitors as Potential Therapeutic Agents in Cancer and HIV Infection
Current Medicinal Chemistry Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued)